Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer

PURPOSE: The combination of an mTOR inhibitor with 5-fluorouracil-based anticancer therapy is attractive because of preclinical evidence of synergy between these drugs. According to our phase I study, the combination of capecitabine and everolimus is safe and feasible, with potential activity in pan...

Descripción completa

Detalles Bibliográficos
Autores principales: Kordes, S., Klümpen, H. J., Weterman, M. J., Schellens, J. H. M., Richel, D. J., Wilmink, J. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4441736/
https://www.ncbi.nlm.nih.gov/pubmed/25822310
http://dx.doi.org/10.1007/s00280-015-2730-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4441736/
https://www.ncbi.nlm.nih.gov/pubmed/25822310
http://dx.doi.org/10.1007/s00280-015-2730-y

Ejemplares similares